Uptake of prenatal genetic diagnosis and termination of pregnancy by Omani Muslim families at risk of genetic disorders: experience over a 9-year period

Abstract

Studies on the acceptance of prenatal diagnosis and termination of pregnancy for single gene disorders within Islamic societies in the Middle East are limited. A few have examined the attitudes toward pregnancy termination for fetal indications, but a dearth of published data exists on actual behavior and uptake. This study reports on all prenatal diagnosis requests for single gene disorders, from the Sultanate of Oman, over 9 years. A retrospective study was conducted during which the medical records of all women who performed prenatal diagnoses for single gene disorders were reviewed. A total of 148 invasive procedures were performed for 114 families. The total number of yearly requests for prenatal diagnosis increased exponentially from three in 2012 to 21 in 2020. Sixty-four different diagnoses were tested for with the majority being autosomal recessive in nature. Seventy-one percent (28/39) of cases where an affected pregnancy was identified were terminated. Fifty-two of the 114 women (45.6%) repeated prenatal diagnosis in a future pregnancy. Seventy-two couples (63%) were consanguineous parents related as second cousins or closer. The majority of tests performed were for couples from Muscat (27%), Albatinah (27%), and Alsharqiya (20.3%) governorates in Oman. The findings of this study provide evidence that prenatal diagnosis is an acceptable reproductive option to prevent the occurrence of genetic disorders that meet termination eligibility criteria as outlined by the Islamic Jurisprudence (Fiqh) Council Fatwa, among Omani Muslim couples.

Introduction

The incidence of genetic diseases and congenital anomalies in the Arab world is known to be significantly higher than in Western countries. In the Sultanate of Oman, located in the south-eastern part of the Arabian Peninsula and bordered by the United Arab Emirates, Saudi Arabia, and Yemen, these figures reach 7% as compared to the 2–3% reported globally (Modell 2002; Rajab et al 2013, 2014). The increased prevalence of the genetically determined disorders has been largely attributed to consanguinity and the preference for tribal and clan endogamy, as is customary for most Arab communities (Al-Gazali et al 2006; Al-Thihli et al 2014; Bittles 2001; Bittles and Hamamy 2010; Bruwer et al 2014; Rajab and Patton 2000). The national survey figures for Oman support high consanguinity rates with 52% of all Omani marriages recorded as consanguineous (Al-Riyami et al. 2000). Rajab and Patton (2000) also reported an average inbreeding coefficient (F) of 0.0198 from their large, clinic-based study, involving more than 60,000 Omani couples (Rajab and Patton 2000). In addition, the authors identified that 36% of marriages were between first and second cousins and 20.4% were classified as marriages between the same tribe. This practice, of consanguineous and endogamous marriage, has partly contributed to the burden of rare recessive genetic disorders in these communities. The additive risk being mainly attributed to shared carrier status for homozygous variants (Al-Gazali et al 2006).

Autosomal recessive disorders are associated with a recurrence risk of 25% for each future pregnancy. Where molecular confirmation has been reached, prenatal genetic diagnosis (PND) can be offered as an option to couples to determine if the pregnancy is affected or not. PND involves an invasive procedure such as chorionic villous sampling (CVS) (offered during the first trimester) or amniocentesis (offered during the second trimester or any later gestational age), to facilitate diagnostic testing for the genetic disorder. While CVS allows for the result at an earlier stage of pregnancy, which has emotional as well as technical benefits as compared to termination undertaken later on, the sensitivity is slightly lower than that of amniocentesis (98% versus 99.9%). The accuracy is affected by the consideration of confined placental mosaicism when sampling chorionic villi (Navaratnam and Alfirevic 2021). Both invasive procedures are associated with a risk of pregnancy loss. Based on a large meta-analysis study, the rate of procedure-related pregnancy loss that is attributable to either CVS or amniocentesis is approximately 0.22% and 0.11% respectively (Akolekar et al 2015). PND services for single gene disorders are available in two tertiary centers in Oman, Sultan Qaboos University Hospital (SQUH) and Royal Hospital (RH). These hospitals offer clinical genetic services and molecular diagnostic laboratories, although PND molecular tests are usually outsourced to overseas molecular diagnostic laboratories. Healthcare is available to all Omani citizens free of charge and the cost for any overseas testing is also financed by the government (Rajab et al 2013).

As many of the rare genetic disorders are not amenable to treatment, PND is usually offered for the purpose of consideration of pregnancy termination. Several studies have already identified that the decision to terminate a pregnancy for a fetal abnormality is known to be linked to the perceived severity of the condition diagnosed (AbdulAzeez et al 2019; Alsulaiman and Hewison 2006; Abramsky et al 2001; Drugan et al 1990) Furthermore, patient acceptance of termination of pregnancy (TOP) as an option is closely related to acceptance of PND (Alkuraya and Kilani 2001, Wertz 1992), as those that may consider TOP are more likely to undertake PND. Islamic jurists have established strict parameters to guide TOP decisions for fetal indications. In 1990, a Fatwa (an Islamic edict) was issued by the Islamic Jurisprudence (Fiqh) Council of the World Islamic League that allowed for termination, for fetal indications, under strict requirements. These requirements included as follows: (1) that the condition is associated with a severe malformation leading to a shortened period of life (2); that the condition should not be amenable to treatment or management; and (3) the diagnosis should be confirmed by three experts. In addition, (4) the request for termination should be electively supported by both the parents. Importantly, (5) the PND and TOP should be performed before 120 days of conception (19-week gestation). This period correlates with the time of ensoulment according to the Hadith (sayings) of the Prophet Mohammed (Al-Matary and Ali 2014; El-Hashemite 1995; Sasongko et al 2010). Certain Islamic schools of thoughts (sects) interpret this time period as 40 days post-conception and for these sects, TOP prior to ensoulment would not be feasible with the available invasive options for PND (Aramesh 2007). Islam is the state religion in Oman, with most of the population practicing Ibadi and Sunni and a minority of communities Shi’a.

In many Arab countries, including Oman, medical termination of pregnancy is still seen as culturally or traditionally unacceptable, with TOP being largely avoided in Muslim communities. In part, the reluctance to accept this as a preventative option may reflect the sect an individual or community follows (Bittles and Hamamy 2010) or unawareness of the Fatwa that governs TOP for fetal indications (Alkuraya and Kilani 2001). Studies on the acceptance of prenatal diagnostic procedures have been mostly conducted in the West and have shown a higher level of uptake than the limited studies performed in the Middle East (Alkuraya and Kilani 2001). A few studies have examined the attitudes toward pregnancy termination with fetal abnormalities within Islamic societies, namely from Saudi Arabia (AbdulAzeez et al 2019; Alkuraya and Kilani 2001; Alshalan and Alfadel 2019; Alsulaiman and Hewison 2006; Gaboon et al 2017). Although anticipated behavior is important when establishing preventative programs, it does not always reflect actual behavior. This study was therefore undertaken to be able to identify the actual uptake of PND for single gene disorders from this part of the world. The present study was carried out at the only two tertiary centers in Oman where PND was performed for single gene disorders from 2012 to 2020. These centers are both located in Muscat, the capital city of Oman.

Method

A retrospective, descriptive study was conducted at SQUH and RH in Oman, during which the medical records of all women who performed CVS or amniocentesis, for a suspected single gene disorder, were reviewed. Invasive testing was offered to these women due to specific ultrasound findings (for example, features suggestive of thanatophoric dysplasia), known molecularly diagnosed case in a previous pregnancy or child or known family history with positive molecular confirmation where premarital genetic testing or carrier testing had confirmed carrier status in parents. Whole exome sequencing and chromosomal microarray, in the prenatal setting, are not offered in Oman and therefore no cases of this nature were included in the study. Information retrieved from medical records included as follows: year of procedure, tribe of the patient, prevalence of consanguinity and regional location, condition tested for including gene and variant details, type of invasive test performed (CVS or amniocentesis), result and outcome of pregnancy-related decisions (for TOP eligible cases). In the absence of detailed national guidelines in Oman governing TOP for fetal indications, internally developed guidelines at the Genetic and Development Medicine Clinic at SQUH were adopted as a standard operating procedure for this purpose (Table 1). The adopted guidelines abide to the Royal Decree governing the practice of the medical profession and allied health professions (Royal Decree 75/2019, 2019). Although other hospitals within Oman are able to offer invasive testing for chromosomal disorders, SQUH and RH are the only two available centers, within the country, where PND for a fetus with a suspected single gene disorder can be facilitated. The information reported in this study, therefore, reflects the trend for the entire country. Formal documentation of PND requests was recorded from 2012, following the inception of the genetic clinic at SQUH in 2011, and therefore depicts the year data collection was initiated from both of the centers. Ethical approval was obtained for the study by the Ethics Committee, College of Medicine and Health Sciences, Sultan Qaboos University (MREC #2071) and the Scientific Research Committee, Royal Hospital (#87/2019).

Table 1.

Criteria to guide termination of pregnancy-related decisions for genetic disorders in Oman

Guidelines defining eligibility for termination of pregnancy of genetic disorders*
Criteria pertaining to the condition	Criteria pertaining to diagnostic confirmation
1. The condition results in severe and debilitating congenital malformations or developmental outcomes or severe organ system dysfunction WITH NO presently available cure or therapy clinically proven to significantly alter these outcomes1 2. The condition is congenital or of infantile onset 3. The natural history of the condition is established. For ultra-rare conditions with poorly established natural history, the condition should have consistently followed the same clinical course among affected relatives in the same families or in families known to the genetic clinic 4. The condition does not show significant variability in severity of the phenotype or in penetrance in a way that impedes reliable prediction of the outcomes	5. The condition is genetically confirmed2 (molecular confirmation or chromosomal where appropriate) 6. Only pathogenic (P) or likely pathogenic (LP) variants (Harrison et al 2019; Richards et al 2015) should be entertained as causative when considering families for prenatal diagnosis 7. Variants reported in clinical laboratories to be of uncertain significance maybe entertained only if reclassified by a clinical laboratory to P/LP based on further information supplied. For example, conclusive evidence from functional studies or clear biochemical perturbations or complete segregation of the variant with the phenotype

¹Families with conditions that have ongoing phase III/IV therapeutic trials may only be considered for termination if they are of congenital, infantile, or of early childhood onset

²Certain conditions may be exempt from molecular confirmation. Examples would include conditions where the phenotype is well known to be lethal and obvious during prenatal diagnostic imagining such as anencephaly, pentalogy of Cantrell, and lethal skeletal dysplasias like achondrogenesis

^*Both condition and diagnostic criteria should be met before termination of pregnancy can be offered as an option

Results

A total of 148 invasive procedures were performed for PND of single gene disorders from January 2012 to December 2020 at the obstetric units at SQUH and RH for 114 families. More CVS procedures (n = 91; 61.5%) were performed than amniocenteses (n = 57; 38.5%) and a significant increase in the number of procedures can be seen per year with a sevenfold increase in the rate of procedures: from three in 2012 to 21 in 2020 (Fig. 1). For six procedures, testing was repeated due to analysis failure following the detection of significant maternal contamination (three were for CVS and three for amniocentesis). Table 2 describes the number of invasive procedures performed in successive pregnancies within the cohort. For 52 of the 114 women (45.6%), PND was requested again in a future pregnancy. A total of 64 different diagnoses were tested for in at-risk pregnancies. The majority of conditions being tested for were inherited in an autosomal recessive manner (61/64; 95.3%), two (2/64; 3.1%) were associated with a dominant inheritance pattern, and one (1/64; 1.6%) with X-linked inheritance. The most frequently requested test performed was for spinal muscular atrophy type 1 (SMA) (17/64; 26.6%), followed by arthrogryposis, renal dysfunction, and cholestasis syndrome (5/64; 7.8%). Table 3 provides further details of the conditions for which PND was performed. The variant details have purposefully been omitted to maintain the privacy of these families. It is not unusual to be able to identify the tribal origin or geographic location of individuals in Oman if the variant details are known for a particular rare condition (Rajab et al 2015). Considering all results where a genetic diagnosis was achieved, 39/142 (27.5%) identified an affected pregnancy and 103/142 (72.5%) an unaffected pregnancy. Of the 39 cases where an affected pregnancy was identified, 28 couples terminated the affected pregnancy (71.8%). For the remaining 11 cases (28.2%) where an affected pregnancy was identified, the information was utilized for management related decisions (planning delivery mode, delivery hospital, future organ transplant planning) for five (45.4%) families and for parental anxiety for seven families (63.6%). Two families opted for TOP abroad for conditions that were not deemed eligible in Oman. Information on individual TOP outcomes (within each disease category) are not included to maintain the privacy of the families’ decisions. Only one report of pregnancy loss was documented following PND, corresponding to a procedure-related loss rate of 0.7% (1/148).

Fig. 1.

Number of prenatal genetic diagnostic tests performed for single gene disorders between 2012 and 2020 (n = 148). Data includes repeat tests performed due to analysis failure. Repeat testing included one case in 2013, 2016, 2017, and 2020 and two cases in 2018

Table 2.

Number of invasive procedures performed in successive pregnancies within the cohort

Number of PND’s undertaken	Number per category	Percentage
Single request for PND	90	60.80%
Repeated PND twice	42	28.40%
Repeated PND three times	6	4.05%
Repeated PND four times	4	2.70%
Repeated PND due to analysis failure	6	4.05%
Total	148	100%

PND, prenatal genetic diagnosis

Table 3.

Genetic disease in cohort of patients undertaking prenatal genetic diagnosis (PND)

	Gene	Condition (OMIM)	Inheritance	Number of tests performed for each conditiona
1	AARS2	Combined oxidative phosphorylation deficiency 8	AR	1
2	AGXT	Primary hyperoxaluria	AR	2
3	ALDH3A2	Sjogren-Larsson syndrome	AR	1
4	ALG12	Congenital disorder of glycosylation, type Ig	AR	1
5	AMPD2	Pontocerebellar hypoplasia, type 9	AR	1
6	ANTXR2	Hyaline fibromatosis syndrome	AR	2
7	AP3B2	Developmental and epileptic encephalopathy 48	AR	1
8	AP3D1	Hermansky-Pudlak syndrome 10	AR	1
9	ARSA	Metachromatic leukodystrophy	AR	3
10	ASL	Argininosuccinic aciduria	AR	1
11	ASPA	Canavan disease	AR	1
12	ATP8A2	Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 4	AR	1
13	B3GALNT2	Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 11)	AR	1
14	CPS1	Carbamoylphosphate synthetase I deficiency	AR	2
15	CTSA	Galactosialidosis	AR	3
16	DGUOK	Mitochondrial DNA depletion syndrome 3 (hepatocerebral type)	AR	2
17	DLAT	Pyruvate dehydrogenase E2 deficiency	AR	1
18	DMD	Duchenne muscular dystrophy	XL	1
19	EIF2AK3	Wolcott-Rallison syndrome	AR	1
20	EMC1	Cerebellar atrophy, visual impairment, and psychomotor retardation	AR	1
21	ERCC5	Xeroderma pigmentosum, group G/Cockayne syndrome	AR	2
22	ETFDH	Glutaric acidemia II	AR	3
23	FBXL4	Mitochondrial DNA depletion syndrome 13 (encephalomyopathic type)	AR	2
24	FGFR3	Thanatophoric dysplasia, type II	AD	2
25	FKTN	Muscular dystrophy-dystroglycanopathy (congenital without mental retardation) type 4B	AR	1
26	FRAS1	Fraser syndrome	AR	1
27	GALC	Krabbe disease	AR	1
28	GAN	Giant axonal neuropathy	AR	1
29	GLB1	GM1-gangliosidosis, type I	AR	1
30	HBB	Beta thalassemia	AR	2
31	HSD17B4	Perrault syndrome 1	AR	1
32	IBA57	Multiple mitochondrial dysfunctions syndrome 3	AR	1
33	IDUA	Mucopolysaccharidosis type I (Hurler)	AR	1
34	IFT172	Short-rib thoracic dysplasia 10 with or without polydactyly	AR	1
35	ITGA8	Renal hypoplasia/aplasia 1	AR	1
36	LAMA3	Epidermolysis bullosa, junctional, Herlitz type	AR	1
37	MPV17	Mitochondrial DNA depletion syndrome type 6	AR	1
38	NAGLU	Mucopolysaccharidosis type IIIB (Sanfilippo B)	AR	1
39	NFASC	Neurodevelopmental disorder with central and peripheral motor dysfunction	AR	1
40	OSTM1	Osteopetrosis	AR	2
41	PC	Pyruvate carboxylase deficiency	AR	1
42	PCCB	Propionic acidemia	AR	1
43	PEX1	Peroxisome biogenesis disorder 1A (Zellweger)	AR	7
44	PEX14	Peroxisome biogenesis disorder 13A (Zellweger)	AR	1
45	PEX26	Peroxisome biogenesis disorder 7A (Zellweger)	AR	2
46	PGAP3	Hyperphosphatasia with mental retardation syndrome 4	AR	1
47	PKHD1	Polycystic kidney disease 4, with or without hepatic disease	AR	1
48	PLA2G6	Neurodegeneration with brain iron accumulation 2B	AR	1
49	PRUNE1	Prune-1 syndrome	AR	3
50	RAB3GAP1	Warburg-Micro syndrome	AR	2
51	RARS	Hypomyelinating leukodystrophy type 9	AR	1
52	RARS2	Pontocerebellar hypoplasia, type 6	AR	1
53	RECQL4	RAPADILINO syndrome	AR	1
54	SMN1	Spinal muscular atrophy-1	AR	17
55	SPINK5	Netherton syndrome	AR	1
56	STT3A	Congenital disorder of glycosylation, type Iw	AR	2
57	SUOX	Sulfite oxidase deficiency	AR	3
58	TBCE	Hypoparathyroidism-retardation-dysmorphism syndrome	AR	3
59	TINF2	Dyskeratosis congenita	AD	1
60	TMEM138	Joubert syndrome 16	AR	1
61	TRIP11	Achondrogenesis, type IA	AR	1
62	TRNT1	Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay	AR	1
63	UGT1A1	Crigler-Najjar syndrome, type I	AR	1
64	VPS33B	Arthrogryposis, renal dysfunction, and cholestasis 1	AR	5

^aData includes repeat procedures. Individual TOP outcomes were not recorded to maintain the privacy of the families’ decisions. AR, autosomal recessive; AD, autosomal dominant; XL, X-linked

Figure 2 illustrates the distribution of couples according to their residence in Oman for the PND’s that were performed. The population size per governorate, as recorded by the 2010 Oman Census data, is also provided on the map (Governorates of Oman 2021). The majority of requests were from the Albatinah (40/148; 27%), Muscat (40/148; 27%), and Alsharqiya (30/148; 20.3%) governorates. Consanguinity was documented for all couples as part of the prenatal genetic counseling session when detailed family pedigrees were recorded. When considering parental relations, 63% (72/114) of couples were consanguineous parents related as second cousins or closer. First cousin marriages were reported in 61 families (53.5%), second cousins in seven (6.1%), double first cousins in two families (1.7%), and first cousins once removed in two families (1.7%). The average coefficient of inbreeding (F) was 0.061. The remainder of couples were endogamous (7/114; 6.2%) and 35 were unrelated (30.7%).

Fig. 2.

Geographic distribution of couples requesting prenatal genetic diagnosis (PND) in Oman. n = PND requests per governorates. P, population size as per 2010 Oman Census data (Governorates of Oman 2021). *Sultan Qaboos University Hospital and Royal Hospital are both located within the capital city of Muscat (Muscat governorate). Albatinah and Alsharqiya are made up of a North and South governorate. PND data for the entire region (North and South) are shown for these two governorates

Discussion

The majority of studies undertaken on PND and TOP have been conducted in Western populations and where reported for the Middle East, have largely focused on the attitudes toward PND and TOP in Saudi-Arabia (AbdulAzeez et al 2019; Alkuraya and Kilani 2001; Alshalan and Alfadel 2019; Alsulaiman and Hewison 2006; Gaboon et al 2017). Although anticipated behavior is useful when determining the need for establishing services, the hypothetical nature is not necessarily predictive of actual behavior. Our study is the first to report on this topic in the Sultanate of Oman. We identified that 114 Omani families utilized PND services for early detection of single gene disorders in an at-risk pregnancy over the 9-year study period with a steady rise in requests for PND from 2012 to 2019. The dip in requests for 2020 can be explained by the impact of COVID-19 on the healthcare system in 2020 including prioritizing COVID-19 patients as well as patient avoidance of hospitals. The border closures in Oman during this year, between governorates, also meant that families interested in PND who lived outside of the Muscat governorate were unable to access services (as both tertiary centers are located within this governorate). Differences in the regional distribution of families undertaking PND (Fig. 2) could also be partly explained by proximity to Muscat, where greater numbers reflect closer proximity to PND services as well as a higher number of requests from more densely populated governorates. The representation from Dhofar region, albeit geographically distant from Muscat, can be explained by the existing collaboration between SQUH and RH and the tertiary hospital in the region and well-established transport routes between the governorates.

Despite CVS being associated with a slightly higher risk of miscarriage and a lower diagnostic accuracy, CVS was preferred to amniocentesis (61.5% versus 38.5%) among the cohort of this study. Although the reasons for this could not be identified from the data, based on our experience with Omani families, a number of explanations could account for this. Primarily, testing in first trimester as opposed to the second trimester carries a benefit in terms of anxiety as well as access to earlier termination. Furthermore, for couples who intend to terminate an affected pregnancy and where close family are not in support of termination, non-disclosure of pregnancy status would be easier in the first trimester when the pregnancy would be less physically apparent. Lastly, as the cut-off period for termination due to fetal indications is 19 weeks, results from repeat testing following amniocentesis may be more likely to fall beyond this period, rendering families without this preventative option. An analysis failure rate of 4% (6/148) was identified in our cohort. This rate is slightly lower than the 6% usually reported for second sampling or repeat procedures (Navaratnam and Alfirevic 2021). Repeat procedures yielded an answer for all cases within the 19-week period, except for one amniocentesis case, where an unaffected fetus was luckily identified at 20-week gestation. Considering the small sample size when calculating our cohort’s miscarriage risk, it would be difficult to compare the procedure-related loss rate of our study to other larger studies; however, our number (1/148; 0.7%) was not significantly higher than figures quoted in the literature (Akolekar et al 2015, Practice Bulletin No. 162 2016).

As Table 3 illustrates, a large percentage of PND requests in Oman were for autosomal recessive genetic disorders. This is not unexpected as Rajab et al (2005), based on a large population-based study involving 420 000 live births from 1993 to 2002, identified autosomal recessive disorders to be the commonest of the genetic disorders within Oman. This increased propensity of some of the recessive disorders has previously been attributed to the practice of consanguinity and endogamous marriages within some of the populations of the Arab communities (Rajab et al 2015). The consanguinity rate of 63% (72/114) in our study is higher than that of the general population (52%) suggesting that consanguinity could be contributing to the increased tendency of occurrence of these otherwise rare autosomal recessive disorders within these families. More commonly occurring recessive disorders, such as SMA and thalassemia, are also listed among the rare recessive disorders for which PND was performed. Although SMA was the most frequently requested PND test, contributing to over 10% (17/148) of PND’s performed, this number is probably an under-representation. For several years, disease-modifying interventions like antisense oligonucleotide therapy became available to families in Oman, with the result that the condition was no longer eligible for termination (and therefore families at-risk of this order may not have considered PND if TOP was not an available option to them). Conditions for which therapeutic options exist that alter the course of the condition are not deemed eligible for termination based on the Fatwa. Thus, haemoglobinopathies, which are known to occur at an incidence of 3.5–4.7/1000 in Oman, one of the highest in the world and the fact that 2–3% of the population are carriers for beta-thalassemia (Al-Riyami and Ebrahim 2003; Rajab et al 2000), also did not contribute significantly to the number of PND requests in the study cohort. Although the Fatwa outlines the conditions that need to be met to be able to offer TOP for fetal indications (addressed in detail earlier), there is no consensus on which fetal anomalies are acceptable indications for TOP. Furthermore, significant differences exist between regional Muslim countries, with regard to the definition of serious medical conditions for which TOP may be considered. To overcome this, organization-specific guidelines, used as standard operating procedures by SQUH and RH, have been used to define objective criteria to guide this process. Table 1 provides an overview of criteria that have been considered when making these decisions in Oman, namely, the condition (classification of severity, age of onset, natural history, and variability in expression and penetrance) and diagnostic confirmation.

Alkuraya and Kilani (2001) and Wertz (1992) have previously shown that the attitude toward termination and request for PND are closely related. Our study provides further support for this among the Omani population as 71.8% of couples terminated the affected pregnancy. As the Fatwa can be used by any Muslim anywhere in the world (Jafri et al 2012), it is important for healthcare professionals to be familiar with the content to enable proper education and counseling of families in accordance with Islam. Based on our personal experience with hundreds of Omani families, patients representing all sects present in the Omani population have requested PND to aid decisions regarding TOP. This suggests that a family’s sect should not be taken as a proxy for their attitudes toward, either for or against, termination of pregnancy. Thus, decisions related to acceptability among individuals from a specific sect should be taken on an individual basis.

The findings of this study provide evidence that PND with the option of TOP for an affected pregnancy is a publicly accepted intervention in Oman. The escalation in the number of requests for PND over the study period together with the fact that 45.6% of couples (52/114) elected to repeat PND in successive pregnancies serves to argue that Omani Muslim couples consider PND a reproductive option to prevent the occurrence of a severe genetic disorder.

Author contribution

All authors contributed to the study design, conception, and material preparation. Data collection and analysis were performed by Zandré Bruwer, Khalsa Al Kharusi, and Salwa Al Ubaidani. The first draft of the manuscript was written by Zandré Bruwer and all authors read and approved the final manuscript.

Declarations

The study was conducted retrospectively from data obtained for clinical purposes. Ethical approval was obtained for the study by the Ethics Committee, College of Medicine and Health Sciences, Sultan Qaboos University, and the Scientific Research Committee, Royal Hospital.

Conflict of interest

The authors declare no competing interests.